CanSino Biologics Inc. reported earnings results for the first quarter ended March 31, 2021. For the quarter, the company reported operating revenue of RMB 466,758,070.10 compared to RMB 4,029,610.40 a year ago. Operating loss was RMB 13,212,305.30 against RMB 23,044,684.44 a year ago. Net loss was RMB 12,774,383.15 or RMB 0.05 per basic and diluted share against RMB 23,100,310.37 or RMB 0.10 per basic and diluted share a year ago.